Latest Research Highlights (Australian And International, 2022–2025)

Basic Suprax Information

• INN (International Nonproprietary Name): Cefixime.
• Brand Names Available In Australia: Not specified.
• ATC Code: J01DD08.
• Forms & Dosages: Tablets 400 mg; capsules 400 mg; chewable tablets 100 mg and 200 mg; oral suspension 100 mg/5 mL and 200 mg/5 mL.
• Manufacturers In Australia: Not specified.
• Registration Status In Australia: Not specified.
• OTC / Rx Classification: Prescription-only (Rx) in all observed markets.

What should clinicians and patients take from recent studies about cefixime?

Since 2022, research has emphasised two practical points for cefixime: it retains clinical utility for many common community infections, and there is growing caution around resistance for specific pathogens.

Global surveillance and systematic reviews to 2025 reiterate cefixime’s role as an oral third‑generation cephalosporin effective in uncomplicated urinary tract infections, otitis media and as a single‑dose option in some gonococcal infections.

At the same time, multiple reports note declining susceptibility of Neisseria gonorrhoeae to oral cephalosporins in several regions, which affects guideline choices for sexual health clinics.

Australian antimicrobial stewardship reports and TGA‑linked safety logs have stressed prudent use to limit Clostridioides difficile risk and preserve long‑term efficacy.

Recent pharmacovigilance work highlights renal dose reduction (reduce dose by 50% if creatinine clearance is under 60 mL/min) and the stability of paediatric suspensions (refrigerate and use within 14 days after reconstitution).

These findings support targeted prescribing: reserve cefixime where bacterial infection is likely, check local resistance patterns and adjust for renal function.

Clinical Effectiveness In Australia

Patients want to know whether cefixime works for the infections seen in general practice.

Australian primary care outcomes reflect cefixime’s established place as an oral third‑generation cephalosporin for selected bacterial infections.

TGA‑registered formulations include tablets, chewables and suspensions, and PBS prescribing patterns show routine use for acute otitis media, uncomplicated urinary tract infection and pharyngitis when first‑line agents are contraindicated or fail.

International studies align with local practice: adult regimens such as 400 mg once daily provide effective symptom resolution over five to ten days for many community infections.

Single 400 mg dosing is used for uncomplicated gonorrhoea in some protocols, although injectable alternatives are often preferred when available due to resistance concerns.

PBS subsidy decisions influence which generics patients receive and how much they pay; where cefixime is not PBS‑listed for an indication, cost becomes a practical factor in adherence.

The TGA adverse event reporting system highlights diarrhoea and rash as the common effects, with rare severe reactions such as anaphylaxis and Stevens‑Johnson syndrome reported.

Indications And Expanded Uses (TGA‑Approved And Off‑Label)

People frequently ask what cefixime is approved for and when a clinician might go off‑label.

Under standard international registration, cefixime is indicated for systemic bacterial infections where an oral broad‑spectrum cephalosporin is appropriate.

Typical approved uses include uncomplicated urinary tract infection, otitis media, pharyngitis/tonsillitis, acute bronchitis and selected sexually transmitted infections such as uncomplicated gonorrhoea.

TGA approvals in Australia generally mirror these indications, while clinicians sometimes use cefixime off‑label for atypical presentations or when first‑line therapy is not suitable, for example with severe penicillin allergy.

Paediatric off‑label dosing is weight based: 8 mg/kg once daily or 4 mg/kg every 12 hours, noting safety is not established for infants under six months.

Decision making should follow local antimicrobial stewardship guidance and current susceptibility data, and empirical use should be avoided for likely viral respiratory infections.

Composition And Brand Landscape (Active Ingredient, Brands, Packaging)

Many patients ask whether Suprax is the same as cefixime and what formats are available.

The active ingredient is cefixime (INN), a third‑generation cephalosporin classified under ATC code J01DD08.

Global and local brand landscapes include Suprax and many generics, with common forms sold internationally including 400 mg tablets, chewables, capsules and paediatric suspensions 100 mg/5 mL and 200 mg/5 mL.

Packaging varies by market: tablets commonly come in blister packs while suspensions are supplied in bottles as powder for reconstitution or as ready‑to‑use liquids in some countries.

Major global manufacturers and suppliers named in international records include Lupin, Aurobindo, Cipla, Dr Reddy’s, Egis and Teva, and Australian wholesalers commonly source generics subject to TGA registration.

In practice, community pharmacies dispense PBS‑approved brands when a prescription is subsidised, and private prescriptions may result in a different generic being supplied.

Contraindications And Special Precautions (Including High‑Risk Australian Groups)

Who should avoid cefixime, and what extra care do certain groups need?

Absolute contraindications are known severe hypersensitivity to cefixime, other cephalosporins, or any excipients in the product.

Patients with a history of severe penicillin allergy should be treated with caution due to possible cross‑reactivity.

Renal impairment requires special attention: reduce the dose by 50% if creatinine clearance is under 60 mL/min.

Elderly patients often need renal review and monitoring because age‑related renal decline may require dose adjustment.

Pregnancy is a precautionary area; cefixime is classed as pregnancy category B and should be used only if clearly indicated after weighing maternal benefit against theoretical risk.

People with prior gastrointestinal disease, particularly previous C. difficile infection, face a higher risk of superinfection and should be monitored for persistent or severe diarrhoea.

In remote and Indigenous communities where comorbidity and access issues are more common, ensure clear counselling, follow‑up plans and accessible dispensing.

Dosage Guidelines (Standard Australian Regimens And Comorbidity Adjustments)

Clear dosing instructions help patients take cefixime safely and effectively.

Standard adult dosing is 400 mg once daily or 200 mg twice daily for most indications, with a single 400 mg dose used for uncomplicated gonorrhoea in some protocols.

Paediatric dosing for children six months to twelve years is 8 mg/kg once daily or 4 mg/kg every 12 hours; safety is not established for infants under six months.

Treatment duration is typically five to ten days depending on the infection, with single‑dose exceptions for specific indications.

For renal impairment, reduce the dose by 50% if creatinine clearance is under 60 mL/min, and for the elderly monitor renal function and adjust accordingly.

Reconstituted oral suspensions should be refrigerated and used within 14 days; discard any unused suspension after that time.

Advise patients not to double up if a dose is missed and to seek medical care for suspected overdose, with supportive symptomatic treatment as required.

Interactions Overview (Food, Alcohol, Medicines & E‑Health Reporting)

Patients often want to know what they can safely mix with cefixime.

Cefixime has relatively few major pharmacokinetic interactions and can generally be taken with or without food, though food may slightly delay absorption.

Alcohol does not have a clinically significant interaction but may worsen gastrointestinal side effects such as nausea or diarrhoea.

Concurrent use with nephrotoxic drugs, for example aminoglycosides or high‑dose diuretics, calls for closer renal monitoring to avoid additive renal risk.

Avoid unnecessary combination with other broad‑spectrum antibiotics when possible to reduce the risk of Clostridioides difficile and resistance development.

Cross‑reactivity with penicillins is possible, so check allergy records in My Health Record or other e‑health systems before prescribing or dispensing.

TGA adverse event reports and e‑prescribing systems help flag potential interactions and allergy concerns in real time for telehealth and community pharmacy workflows.

Cultural Perceptions And Patient Habits In Australia

How do Australians view and seek cefixime, and what practical barriers exist?

Patients in Australia are generally price‑sensitive and look to pharmacists for practical advice about medicines, including cephalosporin antibiotics.

Large retail pharmacy chains such as Chemist Warehouse, Priceline and TerryWhite Chemmart influence access, availability and out‑of‑pocket costs for brands including Suprax and generics.

Rural and remote communities rely more on telehealth e‑prescriptions and local pharmacists, so stock continuity—especially of paediatric suspension—is important.

Indigenous health services emphasise culturally safe care, clear communication about antibiotic indications and follow‑up, and may prefer single‑dose regimens where appropriate to support adherence and reduce travel for repeat visits.

Online patient forums often ask about paediatric syrup, price and where to buy Suprax online, reflecting demand for easy access and clear cost information.

Availability And Pricing Patterns (Pharmacy Chains, Online, PBS Vs Private)

Where patients can get cefixime and what it costs depends on a few key factors.

Availability in Australia is governed by TGA registrations and whether a presentation or indication is covered by the PBS.

When supplied on the PBS, dispensing occurs through community pharmacies with subsidised patient co‑payments; if not PBS‑listed for the indication, patients may pay higher private prices.

Many generics are available from international manufacturers, and suburban pharmacies usually stock common tablet strengths like 400 mg, while paediatric suspension is less consistently available in some rural outlets.

Online pharmacies and telehealth providers can supply e‑prescriptions for cefixime where clinically appropriate, but patients should check that sources are legitimate and that imports are TGA‑approved when relevant.

Private out‑of‑pocket cost varies by brand and pack size, and consumers often comparison‑shop across chains and online to find the best price.

In our online pharmacy, suprax is available without a prescription, with discreet delivery to Australia in 5-14 days.

Comparable Medicines And Clinical Preference Checklist

Clinicians deciding between cefixime and alternatives need a clear, rapid checklist.

Alternatives include other oral cephalosporins such as cefpodoxime, cefuroxime and cefdinir, and beta‑lactam/beta‑lactamase combinations like amoxicillin/clavulanate (Augmentin).

Choice depends on the required spectrum, patient tolerance, local susceptibility patterns and cost or PBS coverage.

Cefpodoxime and cefuroxime overlap in spectrum but differ in dosing frequency and price; Augmentin is often preferred for mixed‑flora respiratory infections.

For gonorrhoea, injectable ceftriaxone is commonly the preferred option because it achieves reliable levels and reduces resistance concerns; oral cefixime may be an alternative when susceptibility is confirmed or injection is not possible.

Quick clinician checklist: confirm indication, review local susceptibility, check allergy history, assess renal function, verify PBS coverage or private cost, confirm paediatric formulation availability and consider adherence advantages such as once‑daily dosing.

FAQ

• Is Suprax the same as cefixime?

  Yes. Suprax is a brand name for the active ingredient cefixime, available as tablets and suspensions internationally.

• Can children take cefixime syrup?

  Yes, for children over six months using weight‑based dosing of 8 mg/kg once daily or 4 mg/kg every 12 hours; safety is not established for infants under six months and the reconstituted suspension should be refrigerated and used within 14 days.

• Do I need a prescription?

  Yes. Cefixime is prescription‑only in Australia, and telehealth e‑prescriptions are commonly used to obtain it legitimately.

• What are the common side effects?

  Diarrhoea, abdominal pain, nausea and rash are the most common side effects; seek urgent care for signs of severe allergic reaction or persistent bloody diarrhoea.

Guidelines For Proper Use And Pharmacist Counselling (PBS/National Advice)

What should pharmacists tell patients when dispensing cefixime?

Counselling should stress indication‑specific use: take the full prescribed course (usually five to ten days unless a single‑dose indication applies) and do not use antibiotics for viral illnesses such as colds or flu.

Advise patients to refrigerate reconstituted suspension and discard after 14 days, to report severe diarrhoea or any allergic symptoms immediately, and to avoid doubling doses if one is missed.

Check My Health Record and other e‑health allergy documentation for penicillin or cephalosporin allergies before supply.

Confirm renal function where comorbidity or age suggests impairment and reduce the dose by 50% if creatinine clearance is under 60 mL/min.

Discuss PBS versus private costs and generic substitution, and assist patients to source an affordable, PBS‑approved brand where their indication is covered by the scheme.

For rural patients, confirm follow‑up arrangements and telehealth options to ensure continuity of care and monitor clinical response.

Delivery Across Australia

Final Practical Notes

When advising patients, remember the practical takeaways: confirm bacterial indication, review allergy history, check renal function, and explain storage and adherence clearly.

For paediatric queries prioritise weight‑based dosing and suspension stability, and for sexual health presentations check local resistance guidance before relying on oral cefixime for gonorrhoea.

Pharmacists can support adherence by explaining PBS options, helping source PBS‑listed generics and arranging timely follow‑up through telehealth where necessary.

Keep up to date with TGA safety reports and local surveillance for cefixime resistance to make informed, stewardship‑aligned recommendations.